Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Common Equity (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Common Equity for 3 consecutive years, with $8.0 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 94.02% to $8.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.0 million through Dec 2025, down 94.02% year-over-year, with the annual reading at $8.0 million for FY2025, 94.02% down from the prior year.
  • Common Equity for Q4 2025 was $8.0 million at Inhibrx Biosciences, down from $36.8 million in the prior quarter.
  • The five-year high for Common Equity was $219.4 million in Q2 2024, with the low at -$24.8 million in Q2 2023.
  • Average Common Equity over 3 years is $81.7 million, with a median of $68.6 million recorded in 2025.
  • The sharpest move saw Common Equity surged 984.11% in 2024, then crashed 94.02% in 2025.
  • Over 3 years, Common Equity stood at $43.5 million in 2023, then soared by 207.07% to $133.6 million in 2024, then plummeted by 94.02% to $8.0 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $8.0 million, $36.8 million, and $68.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.